Evelyn Partners Investment Management LLP Acquires 59,941 Shares of Pfizer Inc. $PFE

Evelyn Partners Investment Management LLP raised its holdings in Pfizer Inc. (NYSE:PFE) by 3,563.7% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 61,623 shares of the biopharmaceutical company’s stock after buying an additional 59,941 shares during the period. Evelyn Partners Investment Management LLP’s holdings in Pfizer were worth $1,494,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Vanguard Group Inc. increased its stake in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the period. Geode Capital Management LLC grew its stake in Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after acquiring an additional 1,820,634 shares in the last quarter. Northern Trust Corp increased its position in shares of Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares during the period. Amundi boosted its holdings in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Finally, Legal & General Group Plc increased its holdings in Pfizer by 3.7% during the 2nd quarter. Legal & General Group Plc now owns 38,444,771 shares of the biopharmaceutical company’s stock worth $931,901,000 after purchasing an additional 1,384,227 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of PFE stock opened at $25.02 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $142.26 billion, a price-to-earnings ratio of 13.31, a PEG ratio of 0.81 and a beta of 0.54. The stock’s 50-day simple moving average is $24.84 and its 200-day simple moving average is $24.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 100.00%.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Bank of America upped their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Scotiabank assumed coverage on Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.